Eli Lilly’s (LLY) remarkable success with its GLP-1 drugs, Mounjaro and Zepbound, has propelled sales growth of 99% and 175% respectively in 2025, now accounting for 56% of the company’s revenues. Despite this impressive performance, the competitive landscape is intensifying, with Novo Nordisk (NVO) and Pfizer (PFE) poised to challenge Eli Lilly’s dominance in the weight-loss drug market.
The current market valuation of Eli Lilly raises concerns for potential investors. With a price-to-earnings (P/E) ratio of 43x, significantly higher than the S&P 500’s average of 28x, much of the company’s success appears to be priced in. As patent protections expire and competition increases, the stock may face downward pressure if earnings do not rise dramatically.
For those considering an investment in Eli Lilly, caution is advised. The stock’s high valuation and competitive risks suggest that it may be wise to explore other opportunities in the pharmaceutical sector. For a deeper dive into these dynamics, I recommend checking out the full article.
Source: fool.com